BLOG

Biotech Rises On Crohn’s Disease Study For Cannabinoid Drug

Arena Pharmaceuticals (ARNA) jumped early Tuesday on promising data for its non-opioid treatment for Crohn’s disease pain. In morning trading on the stock market today, Arena stock lifted 2%, near 43.70, after earlier rising as much as 3.7%. Shares are consolidating with a buy point at 50.15.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}